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1. Introduction 
The prevalence of chronic kidney disease (CKD) is on the rise, and it is estimated that more 
than 26 million Americans suffer from CKD1. The leading risk factors in the development of 
CKD are hypertension (HTN), diabetes mellitus (DM) and obesity. Because of the increasing 
prevalence of these risk factors as well as their frequent coexistence in the same patient, 
prevention strategies that would be able to decrease the progression of CKD to end stage 
renal disease (ESRD) are of paramount importance.  
There is a growing body of evidence showing that the activation of the renin angiotensin 
aldosterone system (RAAS) plays an important role in the development of cardiovascular 
and renal disorders2,3. RAAS is one of the key players in human physiology, and under 
normal physiological conditions it regulates blood pressure homeostasis, water balance, 
renal function and cellular growth. RAAS consists of a cascade of peptide hormones, with 
the enzyme renin catalyzing the first step in a cascade leading to the production of 
angiotensin I (AngI) from a precursor angiotensinogen (Figure 1). The cleavage of 
angiotensinogen, catalyzed by renin, is the rate-limiting step in RAAS activation.  AngI does 
not possess vasoconstricting abilities, and it is cleaved by angiotensin-converting enzyme 
(ACE) into active angiotensin II (AngII). AngII binds to angiotensin receptors and exerts 
powerful vasoconstricting abilities. AngII also activates aldosterone production, and 
regulates sodium and water reapsorption (Figure 1). The kidneys are one of the major 
targets for RAAS as evidenced by the robust expression of RAAS components and receptors 
in the kidney4.  Renal effects of AngII include regulation of renal blood flow, glomerular 
filtration rate (GFR) and sodium and water balance5. Upregulation of renal RAAS has been 
linked to the development of CKD in both HTN and DM4.  
Hence, therapies that modulate RAAS have emerged as essential tools in decreasing the 
progression of CKD. Pharmacological inhibition of RAAS can be obtained via three different 
mechanisms: 1. Inhibition of conversion of AngI to active AngII via angiotensin I converting 
enzyme inhibitors (ACEI); 2. Selective inhibition of angiotensin receptor 1 (AR-1) via 
angiotensin receptor blockers (ARB); 3. Direct inhibition of AngI production via direct 
rennin inhibitors (DRI).  
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Fig. 1. Renin Angiotensin System Activation Cascade and its Effects on Target Tissues 
In this chapter we will summarize the role of RAAS inhibitors on renal outcomes obtained 
from large clinical outcome trials. Clinical outcome trials have become an essential tool in 
evaluating treatment strategies and are now a cornerstone of evidence-based medicine. In 
addition, we will outline future RAAS modulation strategies that may become an important 
part of the clinical armamentarium for renal protection and prevention of CKD in the future.  
2. ACEI in patients with type 1 diabetes mellitus and nephropathy  
Patients with DM are more prone to cardiovascular and renal complications. Diabetic 
nephropathy is the leading cause of ESRD in developed countries 6-8. Even small amount of 
albumin in the urine (microalbuminuria) strongly predicts the development of diabetic 
nephropathy9. Since RAAS plays one of the most important roles in renal physiology, several 
clinical studies have been conducted to evaluate the effect of ACEI on the progression of 
diabetic nephropathy10-12. The landmark study by Lewis et al. [1993], examined the effect of 
ACEI captopril on the progression of diabetic nephropathy in patients with type 1 diabetes 
mellitus (T1DM)13. The primary endpoint was defined as doubling the serum creatinine to at 
least 2 mg/dL. Treatment with captopril was associated with a 48% risk reduction for 
doubling the serum creatinine as compared to the placebo. The beneficial effects of ACEI on 
the progression of diabetic nephropathy were subsequently confirmed by the results of two 
large randomized clinical trials in the patients with T1DM11,12. The North American 
Microalbuminemia Study Group evaluated whether ACEI captopril reduces the progression of 
microalbuminuria to overt diabetic nephropathy in 409 normotensive patients with T1DM11. 
The primary outcome was the progression of microalbuminuria (defined as albumin excretion 
rate of 20-200 µg/min) to clinical proteinuria (defined as albumin excretion rate of > 200 
µg/min, and at least 30% above the baseline). Over a median 3 year follow-up period, patients 
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receiving captopril had a 67.8% risk reduction as compared to those receiving the placebo. 
According to the results of this clinical trial, for every 8 patients treated with captopril, the 
progression to proteinuria will be prevented in 1 patient in a 2-year period11. The EURODIAB 
controlled trial of lisinopril in insulin dependent diabetes (EUCLID) studied 530 normotensive 
T1DM patients either with little or no albuminuria (normoalbuminuria, albumin excretion rate 
< 20 µg/min) or with microabuminuria (albumin excretion rate > 20 µg/min)12. After a 2-year 
follow-up, the albumin excretion rate was 18.8% lower in patients who received lisinopril. 
When patients with normoalbuminuria and microalbuminuria were examined separately, the 
relative treatment difference was 49.7% in the microalbuminuric group and only 12.7% in the 
normoalbuminuric group. A stratified analysis of the normoalbuminuric group showed that 
most of the beneficial effect occurred in patients with albumin excretion rate >5 µg/min12. A 
meta-analysis of 12 clinical trials examining the effect of ACEI on T1DM confirmed the 
protective effect of ACEI on the progression of diabetic nephropathy in T1DM patients14. 
T1DM patients with higher urinary albumin excretion rates appear to achieve a greater benefit 
from RAAS blockade with ACEI14.  
A summary of the clinical trials on RAAS inhibition in T1DM patients with nephropathy is 
presented in Table 1. 
 
Study ACEI 
Number 
of Patients
Renal Outcome 
Risk 
Reduction (%) 
Reference 
Collaborative Study 
Group 
Captopril 207 
Doubling baseline 
creatinine 
43 13 
North American 
Microalbuminuria 
Study Group 
Captopril 215 
Progression to 
clinical proteinuria 
(AER > 200µg/min)
67.8 11 
EUCLID Lisinopril 530 
Change in AER in all 
patients 
Change in AER in 
normoalbuminuric  
patients 
Change in AER in 
microalbuminuric 
patients 
18.8 
 
12.7 (NS) 
 
 
49.7 
12 
ACEI: Angiotensin converting enzyme inhibitor; AER: Albumin Excretion Rate; NS: not significant 
Table 1. Clinical Trials in Patients with Type 1 Diabetes Mellitus and Nephropathy 
3. ACEI and ARB in type 2 diabetes mellitus and nephropathy 
Nephropathy secondary to type 2 diabetes mellitus (T2DM) accounts for the majority of the 
increase in incidence and prevalence of renal failure in the last two decades. Healthcare costs 
for patients with ESRD are already reaching more than $18 billion per year in the United States 
and are on the rise. Since ACEIs have been shown to provide renal protection in patients with 
T1DM and microalbuminuric nephropathy11-13, it was of paramount interest to examine 
whether ACEIs have similar effect in patients with T2DM. The MICRO-HOPE substudy of the 
HOPE trial examined the effect of ACEI ramipril on the development of nephropathy in 3,577 
patients with type 2 diabetes mellitus (T2DM)6,15. Over a 4.5 year follow-up period, treatment 
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with ramipril decreased the risk of development of overt nephropathy by 24%. However, in 
the follow-up analysis no change in the slope of serum creatinine rise or in the incidence of 
doubling serum cratinine was observed15. The Bergamo Nephrologic Diabetes Complication 
(BENEDICT) trial randomized 1,204 T2DM hypertensive patients with normal baseline renal 
function to receive ACEI trandolapril, calcum channel blocker verapamil or combination 
therapy (trandolapril plus verapamil). The primary endpoint was the development of 
persistent albuminuria. After a 3 year follow-up, patients who received trandolapril had a 
lower incidence of albuminuria, and the effect was not enhanced with the addition of 
verapamil16. The effect of verapamil alone was similar to that of the placebo16. Since the 
development of albuminuria is a major risk factor for the cardiovascular complications and 
death in this patient population, the authors concluded that in T2DM hypertensive patients 
with preserved renal function, ACEIs may be the treatment of choice16. In the subsequent 
BENEDICT-B trial they examined the effects of the addition of verapamil on trandolapril 
therapy in hypertensive T2DM petients with established microalbuminuria17. The BENEDICT-
B trial showed that addition of verapamil did not improve albuminuria in T2DM patients with 
nephropathy. Conversely, the trandolapril treatment caused a reduction of albuminuria in 50% 
of the patients, and this reduction translated to a significantly lower rate of cardiovascular 
complications in these patients 17. These results are in sharp contrast to the DIABHYCAR 
study, which failed to show the beneficial effect of ACEI ramipril on cardiovascular and renal 
outcomes in T2DM patients with established albuminuria18.  The lack of an effect due to 
ACEIs in the DIABHCYAR study may be attributed to a mixed patient population; both 
normotensive and hypertensive T2DM patients with albuminuria were included in the study.  
The renal protection effect of ARB in patients with T2DM was studied extensively in the 
early 2000s. Two studies, the Irbesartan in Patients with Diabetes and Microalbuminuria 
(IRMA-2) and the Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study, 
examined the effect of ARB in T2DM patients with microalbuminuria, but without overt 
diabetic nephropathy19,20. In patients with T2DM the presence of microalbuminuria 
increases the risk of development of diabetic nephropathy (defined as albumin excretion 
rate > 200 µg per minute) by a factor of 10 to 20. The IRMA-2 study showed that treatment 
with irbesartan significantly reduces the rate of progression of microalbuminuria to overt 
diabetic nephropathy in patients with T2DM19. Furthermore, the study revealed that 
treatment with irbesartan was associated with significantly more common restoration of 
normoalbuminuria as compared to standard therapy19. All these effects were achieved 
independently of the systemic blood pressure. The DETAIL study compared renoprotective 
effects of ACEI enalapril and ARB telmisartan20. In this head-to-head comparison of these 
two classes of RAAS inhibitors, the authors showed that both enalapril and telmisartan were 
equally effective in preventing the progression of renal dysfunction, measured as a decline 
in the GFR20. Two other studies, the Reduction of Endpoints in NIDDM with Angiotensin II 
Antagonist Losartan (RENAAL) and the Irbesartan Diabetic Nephropathy Trial (IDNT) 
examined patients with T2DM, but with a higher rate albuminuria and established renal 
insufficiency 10,21. In the RENAAL study, treatment with ARB losartan was associated with a 
25% reduction of risk for doubling serum creatinine level and the risk of developing ESRD 
was reduced by 28%21 Again, the favorable effect seemed to be independent of blood 
pressure effect. The IDNT compared the effect of ARB irbesartan and calcium-channel 
blocker amlodipine against the progression of nephropathy10. The primary endpoint was a 
composite of doubling the serum creatinine concentration, development of ESRD, renal 
transplantation and death. IDNT revealed that irbesartan decreased the relative risk of 
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reaching the primary end point by 20% when compared to the placebo and by 23% when 
compared to amlodipine. IDNT data showed that the renoprotective effect of irbesartan in 
patients with T2DM and overt nephropathy is due to the slowing of the progression of 
glomerulopathy10.  The Incipient to Overt: Angiotensin II Blocker Telmisartan, Investigation on 
Type 2 Diabetic Nephropathy (INNOVATION) study examined the effect of ARB telmisartan 
in 527 normotensive and hypertensive T2DM Japanese patients with microalbuminuria22-24. 
After a follow-up of 52 weeks, transition to overt nephropathy was significantly lower with 
telmisartan23,24. In a trial comparing telmisartan versus losartan in T2DM patients with overt 
nephropathy (AMADEO) both agents reduced blood pressure, however telmisartan was more 
effective in reducing albuminuria as compared to losartan25. In the head to head comparison of 
ACEI ramipril and ARB telmisartan (ONTARGET) study, an increase in urinary albumin 
secretion was significantly lower in the telmisartan group as compared to ramipril26,27.  
A summary of the clinical trials in patients with T2DM and nephropathy is outlined in Table 2. 
 
Study ACEI or ARB 
Number of 
Patients 
Renal Outcome Risk Reduction (%) Reference 
MICRO-HOPE Ramipril (ACEI) 3,577 Overt nephropathy 24 6, 15 
BENEDICT 
Trandolapril (ACEI) 
with or without 
verapamil 
1,204 
Development of persistent 
albuminuria (>200 µg/min) 
Delay of onset of 
albuminuria by factor 2.1 
16 
BENEDICT-B 
Trandolapril (ACEI) 
vs. 
Trandolapril/Verapa
mil 
281 
Development of persistent 
albuminuria (UAE >200 µg/min)
NS (between trandolapril 
alone vs. 
trandolapril/verapamil) 
17 
DIABHYCAR Ramipril (ACEI) 4,912 
Combined incidence of 
cardiovascular death, non-fatal 
myocardial infarction, stroke, 
heart failure leading to hospital 
admission, and end stage renal 
failure 
0.97 (NS) 
18 
 
IRMA-2 Irbesartan (ARB) 590 
Development of persistent 
albuminuria (UAE  >200 µg/min, 
or ≥ 30% from baseline) 
HR 0.56 (150 mg group) 
HR 0.32 (300 mg group) 
19 
DETAIL 
Telmisartan (ARB) 
vs. enalapril (ACEI) 
250 Change in GFR ARB not inferior to ACEI 20 
RENAAL Losartan 1,513 
Composite of doubling serum 
creatinine, ESRD or death 
25 21 
IDNT 
Irbesartan (ARB) vs. 
amlodipine 
1,715 
Doubling baseline serum 
creatinine, onset of ESRD, serum 
creatinine of 6mg/dL and death 
from any cause 
20 (vs. placebo 
23 (vs. amlodipine) 
10 
INNOVATION Telmisartan (ARB) 527 
Transition rate from incipient 
to overt nephropathy (UACR  > 
300 
mg/g and increase ≥ 30% from 
baseline) 
55 23,24 
AMADEO 
Telmisartan (ARB) 
vs. Losartan (ARB) 
860 Change in UPC from baseline 
Telmisartan superior to 
losartan (29.8% vs. 21.4% 
reduction) 
25 
ONTARGET 
Ramipril (ACEI), 
Telmisartan (ARB) or 
both 
25,620 
Composite of dialysis, doubling of 
serum creatinine, and death 
HR 1.00 (Ramipril vs 
Telmisartan) 
HR 1.09 Combination 
Therapy 
27 
ACEI: Angiotensin converting enzyme inhibitor; AER: Albumin Excretion Rate; GFR: Glomerular 
Filtration Rate; UACR: Urinary albumin-to-Creatinine ratio; UPC: Urinary Protein-to-Creatinine;  
HR: Hazard Ratio;  NS: not significant 
Table 2. Clinical Trials in Patients with Type 2 Diabetes and Nephropathy 
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As a result of the renoprotective effect of RAAS blockade in T1DM and T2DM patients with 
established albuminuria, the American Diabetes Asociation (ADA) recommends using ACEI 
and ARBs in diabetic patients with nephopathy28. Specifically, the ADA recommends ACEI 
in hypertensive T1DM patients with albuminuria and ACEI or ARB in hypertensive T2DM 
patients with albuminuria. In hypertensive T2DM patients with already established renal 
insufficiency, ARBs are recommended as a first line of treatment28.  
Even though ACEIs and ARBs have become a cornerstone of treatment of diabetic patients 
with established nephropathy (secondary prevention), it is still unclear whether RAAS 
blockade may be beneficial in preventing renal damage in diabetic patients without 
proteinuria. More recent clinical trials focused on the effect of ACEIs and ARBs on 
normotensive diabetic patients with normal renal function in order to examine whether 
early RAAS inhibition could prevent the development of renal disease in this patient 
population. It is estimated that about 20-30% of T1DM and T2DM patients develop 
nephropathy over the course of their illness28. The DIRECT program was established to 
investigate the effect of ARB candersartan in the development of diabetic retinopathy, and 
as a secondary outcome it addressed the effect of candersartan in the primary prevention of 
diabetic nephropathy (DIRECT-Renal)29. They included 3,326 T1DM and 1,905 T2DM 
patients, and after a follow up of 4.7 years, candersartan did not prevent microalbuminuria 
in normotensive patients with either T1DM or T2DM29. The Telmisartan Randomised 
Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) 
examined the effect of ARB telmisartan on cardiovascular outcomes in ACEI intolerant 
patients26,30. In this multicenter multinational study they included 5,926 diabetic patients 
with known cardiovascular disease, but without microalbuminuria. After 56 months follow-
up, no important difference was found in the composite renal outcome (dialysis, doubling 
serum creatinine, changes in albuminuria and GFR) between patients treated with 
telmisartan versus placebo30. In the Renin–Angiotensin System Study (RASS), the authors 
examined whether a blockade of RAAS with either ACEI enalapril or ARB losartan prevents 
the development of structural glomerular changes consistent with the nephropathy in renal 
biopsy specimens of 285 normotensive T1DM patients with preserved GFR31. The results 
showed no significant difference in the progression of glomerular structural changes among 
the treatment groups31.   
Taken together, the present evidence does not support the use of ACEI or ARB in the 
primary prevention of diabetic nephropathy in patients with T1DM or T2DM. 
A summary of the clinical trials in patients with DM and without HTN and nephropathy is 
presented in Table 3. 
4. Direct renin inhibitor aliskiren and renal protection 
The recent discovery of (pro)rennin receptor has added a new perspective to the RAAS 
physiology, and has opened new avenues for drug development and RAAS targeting32. It 
has became clear that both prorenin and renin can bind to (pro)renin receptors and activate 
intracellular signal transduction pathway, independent of angiotensin receptor 
activation33,34. Activation of the (pro)rennin receptor-mediated pathway results in 
glomerular fibrosis, due to upregulation of transforming growth factor β (TGF β) and 
increased synthesis of plasminogen activator inhibitor-1 and fibrotic glomerular matrix 
components, fibronectin and collagen I (Figure 1)35.  
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Study ARB 
Number of 
Patients 
Renal Outcome 
Risk  
Reduction (%) 
Reference 
DIRECT-Renal 
Candesartan 
(ARB) 
3,326 
T1DM 
1,905 
T2DM 
Primary 
Prevention of 
Diabetic 
Nephropathy 
(secondary 
outcome) 
NS over 
placebo 
29 
TRANSCEND 
Telmisartan 
(ARB) 
5,926 
Composite renal 
outcome 
(Dialysis, 
doubling serum 
creatinine, 
changes in 
albuminuria and 
GFR) 
NS over 
placebo 
30 
ARB: Angiotensin Receptor Blocker; GFR: Glomerular Filtration Rate; NS: not significant 
Table 3. Clinical Trials in Patients with Diabetes Mellitus without Hypertension and 
Proteinuria (Primary Prevention) 
DRI aliskiren is the newest addition to RAAS blocking agents36. Preclinical studies offered 
very attractive effect of aliskiren in renal protection in diabetic and non-diabetic models of 
CKD. Aliskiren has been shown to have antihypertensive and a renoprotective effect in 
diabetic experimental nephropathy37. The profound effect of aliskiren on renal RAAS was 
due to selective renal accumulation (aliskiren renal/plasma concentration ratio of 60)37. The 
promising preclinical renoprotective effect of aliskiren was then tested in clinical trials in 
patients with diabetic nephropathy. In the largest to date Aliskiren in the Evaluation of 
Proteinuria in Diabetes (AVOID) study, 599 patients with T2DM, hypertension and 
nephropathy were enrolled38. The addition of aliskiren to the maximum renoprotective dose 
of ARB losartan further reduced albuminuria by 20%38. The reduction of albuminuria was 
achieved despite a non-significant decrease in blood pressure, suggesting that the 
renoprotective effect of aliskiren was independent of the blood pressure control38,39. In the 
subsequent AVOID subanalysis, aliskiren was found to decrease urinary aldosterone level, 
which may be partially responsible for the additional renoprotective effect of aliskiren seen 
in the AVOID study40.  The ongoing Aliskiren Trial in Type 2 Diabetic Nephropathy 
(ALTITUDE) study will give further insights into whether a dual RAAS blockade with 
either ACEIs or ARBs in combination with DRI aliskiren is beneficial in preventing 
progression of nephropathy in T2DM41. 
5. Controversies of dual RAAS blockade 
5.1 Rationale for dual ACEI and ARB therapy 
Despite proven efficacy of ACEIs and ARBs in decreasing the progression of renal decline 
and cardiovascular complications in patients with DM and nephropathy, residual 
cardiovascular and renal complications are still high42. Dual RAAS inhibition has a 
theoretical advantage over single therapy, since all classes of drugs that target RAAS have 
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been proven to possess renal and cardiovascular protective effects. The rationale of dual 
blockade lies in the fact that inhibition of AngII production by ACEIs cause an increase in 
AngI levels, and increased levels of AngI lead to additional production of AngII via ACE-
independent pathways (ACE escape). Blockade of AT1 receptors by ARBs leads to a 
compensatory increase of AngII43, which may partly offset AT1 blockade by ARB (AngII 
escape). Dual blockade with ACEIs and ARBs has a theoretical advantage over 
monotherapy, since it may offer a more effective overall inhibition of RAAS. However, 
results from large clinical trials have been inconsistent. The results from the Combination 
treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in 
non-diabetic renal disease (COOPERATE) trial, which was the only large clinical trial so far 
showing improved renal outcomes with combination ACEI/ARB therapy, were recently 
retracted due to inconsistencies in the data44,45. In the OTNTARGET study, dual blockade 
with ACEI ramipril and ARB telmisartan was associated with worse renal outcomes and an 
increased risk of acute renal failure27. Subgroup analysis of the ONTARGET data showed 
that a dual blockade was harmful primarily in patients with a low renal risk, which does not 
exclude the potential benefit of a dual ACEI/ARB blockade in patients with high renal risk 
(i.e. patients with DM and nephropathy).  
Ongoing studies on dual ACEI/ARB blockade in patients with DM and nephropathy: 
Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor 
for Treatment of Diabetic Nephropathy (VA NEPHRON-D)46 and the Long-term Impact of 
RAS Inhibition on Cardiorenal Outcomes (LIRICO)47 are designed specifically to assess 
ACEI/ARB combination therapy in high risk patients. The VA-NEPHRON-D will assess 
combination of ACEI lisinopril and ARB losartan on the progression of kidney disease in 
patients with DM and nephropathy46. The LIRICO trial will evaluate the cardiovascular and 
renal effects of ACEI/ARB combination therapy in patients with preexisting albuminuria 
and at least one more cardiovascular risk factor (cigarette smoking, DM, HTN, visceral 
obesity, dyslipidemia, or family history of cardiovascular diseases)47. Results of these 
studies should provide more information on the usefulness of dual ACEI/ARB therapy in 
high risk patients.  
5.2 Rationale for ACEI/ARB and DRI combination therapy 
Both ACEI and ARB therapy cause a compensatory increase of plasma rennin activity (PRA) 
up to 15-fold48,49. High PRA has been shown to increase the risk of myocardial infarction in 
patients with HTN50, and is associated with increased mortality in patients with heart 
failure51.  DRI aliskiren inhibits ~75% of PRA, and selectively accumulates in the kidney52. 
Thus, combination therapy of aliskiren and either ACEIs or ARBs may provide an 
additional benefit especially in patients with preexisting renal impairment and high PRA. 
As previously mentioned, the AVOID study offered promising results of ARB and DRI 
combination therapy in T2DM patients with nephropathy39,40. The ongoing ALTITUDE 
study will assess combination therapy with either ACEI or ARB and DRI aliskiren in 8,600 
T2DM patients with nephropathy and/or cardiovascular disease. The primary endpoint is 
the time to first event for the composite endpoint of cardiovascular death, resuscitated 
death, myocardial infarction, stroke, unplanned hospitalization for heart failure, onset of 
ESRD or doubling of baseline serum creatinine concentration41. 
A summary of the clinical trials evaluating combination RAAS therapy is presented in  
Table 4. 
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Study 
Combination 
Therapy 
Number 
of 
Patients
Renal Outcome Risk Reduction (%) Reference 
COOPERATE ACEI/ARB RETRACTED (Inconsistency of data) 44,45 
ONTARGET 
Ramipril 
(ACEI), 
Telmisartan 
(ARB) or both 
25,620 
Composite of dialysis, 
doubling of serum creatinine, 
and death (primary endpoint)
Dialysis, doubling serum 
creatinine (secondary 
endpoints) 
HR 1.09 for primary 
outcome 
HR 1.24 for secondary 
outcome 
Worse renal outcome 
and increased risk of 
ARF in combination 
group 
27 
VA 
NEPHRON-D 
Combination 
Lisinopril 
(ACEI) and 
Losartan (ARB)
 
Time to reduction in eGFR 
>50%, ESRD and death 
Ongoing 46 
LIRICO 
Combination of 
ACEI and ARB
2,100 
ESRD and Renal function 
(secondary outcome) 
Ongoing 47 
AVOID 
Combination of 
losartan (ARB) 
and aliskiren 
(DRI) 
599 
Changes in UACR and eGFR 
(post hoc analysis) 
Significant difference 
in number of patients 
with a >50% reduction 
in UACR from 
Baseline 
Reduction in eGFR 
decline only in group 
with HTN >140/90 
mmHg  at baseline 
39, 40 
ALTITUDE 
Combination of 
aliskiren (DRI) 
with either 
ACEI or ARB 
8,600 
Time to first event for the 
composite endpoint of 
cardiovascular death, 
resuscitated death, myocardial 
infarction, stroke, unplanned 
hospitalization for heart 
failure, onset of ESRD or 
doubling of baseline serum 
creatinine concentration 
Ongoing 41 
ACEI: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker; DRI: Direct 
Renin Inhibitor; AER: Albumin Excretion Rate; HR: hazard ratio; ARF: Acute Renal Failure; ESRD: End 
Stage Renal Disease; eGFR: estimated Glomerular Filtration Rate; UACR: Urinary Albumin Creatinine 
Ratio; NS: not significant 
Table 4. Clinical Trials with Dual Renin Angiotensin System Blockade 
Ongoing and future studies should answer questions regarding safety and efficacy of RAAS 
combination therapy, as well as to to assess specific patient populations that may benefit 
from a more intense RAAS blockade. 
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